Newsroom | 5389 results

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the...

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the im...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), a leading consumer healthcare company focused on helping people achieve their best health, today announced improved Star Ratings for 2027, highlighted by 95% of its Medicare Advantage members being enrolled in plans rated 4.0 stars or above by the Centers for Medicare and Medicaid Services (CMS). Additionally, 42% of Humana Medicare Advantage members are enrolled in 4.5-star plans for 2027.“We’re extremely proud of these Star Ratings. Th...

BASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TYO 6523), today announced a strategic partnership with venture-backed health technology startup Sava Technologies to support the introduction and future commercialization of its innovative wearable microsensor. The partnership comprises an exclusive commercialization and distribution agreement, initially in Europe, and a concurrent financing agreement. Under t...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospital admiss...

WIXOM, Mich.--(BUSINESS WIRE)--This marks the 3rd consecutive year that Rockwell Medical earned this recognition—climbing the ranks from #50 (2024) and #40 (2025) to #16 (2026)....

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program’s largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l...

LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, announced today that it has named two accomplished healthcare leaders: Laurie Sicaeros as president of City of Hope Cancer Center Arizona and Melissa Childress as president of City of Hope Cancer Center Atlanta. Both leaders have built careers on improving patient access and strengthening healthcare systems in their communities. As cancer rates cont...